Inventor · disambiguated record

Stefan Stevanovic

Also filed as: STEVANOVIC STEFAN

52 granted patents·11 pending applications·541 citations·filing 1992–2023

98Inventor score

Technology areasA61K A61P G01N C12N C07K

Files withIMMATICS BIOTECHNOLOGIES GMBH51 RAMMENSEE HANS GEORG4 WEINSCHENK TONI4 LUDWIG INST CANCER RES2 MAX PLANCK GESELLSCHAFT1

Top patents by PatentIndex Score

63 records

0197US10434136B2Powerful MHC-class II peptides derived from survivinIMMATICS BIOTECHNOLOGIES GMBH·Filed 2013·Granted Oct 8, 2019·47 cites·3 claims
0296US10286052B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted May 14, 2019·25 cites·17 claims
0396US10167317B1Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Jan 1, 2019·6 cites·18 claims
0496US9498512B2Powerful MHC-class II peptides derived from survivinRAMMENSEE HANS-GEORG·Filed 2012·Granted Nov 22, 2016·56 cites·5 claims
0596US8647629B2Powerful MHC-class II peptides derived from survivinRAMMENSEE HANS-GEORG·Filed 2009·Granted Feb 11, 2014·56 cites·8 claims
0696US8008431B2Tumor-associated peptides that bind to MHC-moleculesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2005·Granted Aug 30, 2011·49 cites·19 claims
0795US10144763B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Dec 4, 2018·5 cites·18 claims
0895US10064924B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2015·Granted Sep 4, 2018·24 cites·17 claims
0994US10000533B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2015·Granted Jun 19, 2018·5 cites·4 claims
1094US9023804B2HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereofWEINSCHENK TONI·Filed 2011·Granted May 5, 2015·12 cites·22 claims
1194US7666984B2Tumour-associated peptides binding to MHC-moleculesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2007·Granted Feb 23, 2010·18 cites·2 claims
1293US11957729B2Powerful MHC-class II peptides derived from survivinIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Apr 16, 2024·4 cites·14 claims
1393US8536304B2Tumour-associated peptides that bind to MHC moleculesWEINSCHENK TONI·Filed 2010·Granted Sep 17, 2013·16 cites·10 claims
1493US8399613B2Tumour-associated peptides that bind to MHC moleculesWEINSCHENK TONI·Filed 2010·Granted Mar 19, 2013·15 cites·13 claims
1593US7763711B2Tumour-associated peptides binding to MHC-moleculesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2007·Granted Jul 27, 2010·15 cites·12 claims
1692US10364271B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Jul 30, 2019·2 cites·23 claims
1791US10377797B2Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Aug 13, 2019·13 cites·25 claims
1891US10196422B2Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2016·Granted Feb 5, 2019·13 cites·16 claims
1991US7396904B2Tumor-associated peptides binding to MHC-moleculesIMMATICS BIOTECHNOLOGIES GMBH·Filed 2004·Granted Jul 8, 2008·25 cites·2 claims
2090US11542303B2Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Granted Jan 3, 2023·1 cites·9 claims
2189US10450346B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Oct 22, 2019·1 cites·20 claims
2286US6548064B1Isolated peptides consisting of amino acid sequences found in SSX or NY-ESO-1 molecules, which bind to HLA moleculesLUDWIG INST CANCER RES·Filed 1999·Granted Apr 15, 2003·51 cites·6 claims
2385US10906938B2Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Feb 2, 2021·1 cites·28 claims
2484US7528224B1Peptide for triggering an immune reaction against tumor cellsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2006·Granted May 5, 2009·8 cites·3 claims
2583US11135246B2Peptides and combination of peptides for use in immunotherapy against leukemias and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Oct 5, 2021·1 cites·22 claims
2681US7087712B1Peptide for triggering an immune reaction against tumor cellsIMMATICS BIOTECHNOLOGIES GMBH·Filed 2000·Granted Aug 8, 2006·12 cites·2 claims
2780US7270819B2Isolated nucleic acid molecules encoding isolated peptides which correspond to contiguous amino acids of an SSX molecule or NY-ESO-1 and uses thereofLUDWIG INST CANCER RES·Filed 2002·Granted Sep 18, 2007·5 cites·4 claims
2879US11560405B2Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Jan 24, 2023·0 cites·20 claims
2979US10570175B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Feb 25, 2020·0 cites·20 claims
3078US10668137B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jun 2, 2020·0 cites·20 claims
3178US8242239B2MHC molecule-binding tumor-associated peptidesWEINSCHENK TONI·Filed 2009·Granted Aug 14, 2012·2 cites·5 claims
3277US10875892B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Dec 29, 2020·0 cites·20 claims
3376US10730910B2Immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (CLL)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Aug 4, 2020·0 cites·20 claims
3475US11559550B2Peptides and combination of peptides for use in immunotherapy against leukemias and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Granted Jan 24, 2023·0 cites·20 claims
3575US10925949B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Feb 23, 2021·0 cites·20 claims
3675US10898562B1Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 26, 2021·0 cites·20 claims
3775US10525115B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jan 7, 2020·0 cites·20 claims
3875US9023802B2HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereofRAMMENSEE HANS GEORG·Filed 2010·Granted May 5, 2015·3 cites·20 claims
3975US5747269ADetermination of peptide motifs on MHC moleculesMAX PLANCK GESELLSCHAFT·Filed 1992·Granted May 5, 1998·50 cites·12 claims
4075US2023346837A1Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2023·Application pending·0 cites
4174US11103534B2Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Aug 31, 2021·0 cites·20 claims
4274US2021213065A1Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2021·Application pending·0 cites
4374US2021107941A1Novel cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Application pending·0 cites
4474US2022332760A1Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2022·Application pending·0 cites
4573US11427614B2Peptides and combination thereof for use in the immunotherapy against cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2018·Granted Aug 30, 2022·0 cites·16 claims
4673US10919933B2Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Feb 16, 2021·0 cites·28 claims
4773US10899794B2Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Jan 26, 2021·0 cites·28 claims
4873US10889617B2Cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancersIMMATICS BIOTECHNOLOGIES GMBH·Filed 2019·Granted Jan 12, 2021·0 cites·28 claims
4973US10813985B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (aml)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Oct 27, 2020·0 cites·20 claims
5073US10799571B2Immunotherapy against several tumors of the blood, such as acute myeloid leukemia (AML)IMMATICS BIOTECHNOLOGIES GMBH·Filed 2020·Granted Oct 13, 2020·0 cites·20 claims

Showing the top 50 of 63 patent records by PatentIndex Score.

Join the waitlist — get patent alerts

Get an alert when Stefan Stevanovic files or is granted a new patent.

We store only your email — no account needed. See our privacy policy.

Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →